Delray Medical Center cut the ribbon on its newest high-tech machine last week that targets brain areas to treat movement ...

“There are things that we can do at all stages of our lives deliberately,” says Prof Schott. “It’s never too early to start ...

New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...

Eisai (ESAIY) and Biogen (BIIB) announced that the FDA has accepted Eisai’s Biologics License Application, BLA, for ...

In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...

The Tennessee Lady Volunteers are set to host its annual “We Back Pat” game at Food City Center on Thursday against ...

Topline results from a phase 2b/3 clinical trial of blarcamesine for individuals with early-stage Alzheimer’s disease showed ...

Having depression is known to increase a person’s risk of developing dementia, but depression is also an early indicator of ...

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...

IGC Pharma, Inc (NYSE American:IGC) (”IGC” or the “Company”), today announced that CEO Ram Mukunda and CCO Claudia Grimaldi ...